Clinical Experience of Dual Targeted Blockade (Pertuzumab + Trastuzumab + Docetaxel) in Neoadjuvant Therapy of Early HER-2-Positive Breast Cancer
2019
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI